<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01223625</url>
  </required_header>
  <id_info>
    <org_study_id>VF-200600</org_study_id>
    <nct_id>NCT01223625</nct_id>
  </id_info>
  <brief_title>Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Endothelial Function</brief_title>
  <official_title>Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Endothelial Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to measure the effect of moderate and intensive lipid-lowering
      treatment with rosuvastatin on the endothelial function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change from baseline in endothelium-dependent flow mediated vasodilatation of the brachial artery.</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in endothelium independent flow mediated vasodilatation of the brachial artery</measure>
    <time_frame>One Year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin 5mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 5mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin 40mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 40mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 5mg/day</intervention_name>
    <description>Rosuvastatin 5mg/day</description>
    <arm_group_label>Rosuvastatin 5mg/day</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 40mg/day</intervention_name>
    <description>Rosuvastatin 40mg/day</description>
    <arm_group_label>Rosuvastatin 40mg/day</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. STEMI

          2. no prior treatment with statins

        Exclusion Criteria:

          1. age below 18 or above 81 years

          2. unconscious patients

          3. serum creatinine &gt; 176Î¼mol/L

          4. total-cholesterol &gt; 7.0 mmol/l

          5. hypothyreoidism ((TSH &gt; 1.5 x ULN (upper limit of normal))

          6. current liver disease (ALAT &gt; 2 x ULN)

          7. unexplained creatine kinase &gt; 3 x ULN

          8. alcohol or drug abuse within the last five years

          9. prior myopathy or serious hypersensitivity reaction caused by statins

         10. women with childbearing potential who were not using chemical or mechanical
             contraception

         11. pregnant or breastfeeding women

         12. history of malignancy unless a disease-free period of more than five years was present

         13. patients with abnormal lung function test (LFT)

         14. participation in another investigational drug study less than four weeks before
             enrolment in the present study

         15. treatment with cyclosporine or fibrates.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>81 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rasmus Egede, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Odense University Hospital, Odense, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <state>Fuenen</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2010</study_first_submitted>
  <study_first_submitted_qc>October 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2010</study_first_posted>
  <last_update_submitted>October 18, 2010</last_update_submitted>
  <last_update_submitted_qc>October 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Rasmus Egede</name_title>
    <organization>Department of Cardiology, Odense University Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

